Lamictal Patent Settlement Allows Teva To Launch Chewable Generic By July
This article was originally published in The Pink Sheet Daily
Executive Summary
Litigation settlement with GlaxoSmithKline will allow Teva to enter the market with a chewable generic more than three years before a Lamictal use patent in epilepsy expires. Teva also can market regular lamotrigine tablets "with an expected launch date in 2008" under the settlement.